sible for endocannabinoid biosynthesis and degradation, is crucially involved in the regulation of hepatic fibrogenesis.
Cannabinoid receptor type 2 (CB2)
Ϫ/Ϫ mice showed increased fibrogenesis in response to carbon tetrachloride (CCl 4 ) injection, whereas CB1 Ϫ/Ϫ mice displayed decreased hepatic fibrogenesis (26, 52) . However, the mechanisms by which endocannabinoids regulate liver injury and fibrogenesis are not well characterized. Although it has been suggested that endocannabinoids promote the resolution of hepatic fibrosis by inducing cell death in hepatic stellate cells (HSCs), the main fibrogenic cell type in the liver, it remains elusive which endocannabinoids are involved in regulation of hepatic fibrogenesis (26, 50 -52) .
Endocannabinoids evoke a wide spectrum of physiological actions that are mostly mediated through the G-protein-coupled cannabinoid receptors CB1 and CB2 (15, 36) but can also occur independently of these receptors (5, 7, 26, 35, 44, 48, 50, 51) . Endocannabinoids were initially described to play major roles in the central nervous system where they regulate food intake, emotions, pain perception, and sleep (16, 17, 27) . More recent studies (28, 33, 39) have shown that endocannabinoids are also involved in the regulation of inflammation, cell death, and peripheral lipogenesis. N-arachidonoyl ethanolamide [anandamide (AEA)] and 2-arachidonoyl glycerol (2-AG) are the best characterized endocannabinoids.
Recently we and others have shown that AEA or 2-AG selectively induce cell death in HSCs (Refs. 6, 21) and therefore hold antifibrogenic properties. Interestingly, N-arachidonoyl dopamine (NADA), a novel endocannabinoid, also selectively induced cell death under certain circumstances in immune or neuronal cells (13, 45) . NADA belongs to the endovanilloid class of endocannabinoids and was recently identified as an endogenous ligand for CB1 and transient receptor potential cation channel subfamily V, member 1 (TRPV1; Refs. 6, 24) . It also shows low affinity to CB2 receptors (6, 16) . In the central nervous system, NADA can be found predominantly in the striatum, hippocampus, cerebellum, and dorsal root ganglia and is proposed to play a role in neuronal pain and inflammation (23) . In peripheral organs such as isolated bronchi or urinary bladder of the guinea pig, NADA showed constrictory effects mediated by TRPV1 signaling (20) . In contrast, NADA initiated vasorelaxant effects also via the activation of TRPV1 and CB1 receptors in small mesenteric vessels, superior mesenteric artery (37) , or aorta in rats (38) . Moreover, NADA induced cell death in a human neuroblastoma cell line or in human peripheral blood mononuclear cells via TRPV1 activation (13, 45) . However, the effect of NADA as a representative of this novel endovanilloid class of endocannabinoids on different liver cell populations and its function in acute or chronic liver diseases have not been elucidated so far.
In this study, we found a specific expression of the ratelimiting NADA-generating enzyme tyrosine hydroxylase (TH) mainly in sympathetic neurons in portal tracts. The expression remained constant in normal or fibrotic liver. Possibly due to a volatile nature and faster degradation in contrast to AEA, NADA was only detectable in the striatum but not in normal or fibrotic liver tissue. NADA selectively induced reactive oxygen species (ROS)-dependent necrotic cell death in primary culture-and in vivo-activated HSCs independently from cannabinoid receptors, whereas primary hepatocytes were resistant against NADA due to high expression of the endocannabinoiddegrading enzyme fatty acid amide hydrolase (FAAH) and high levels of antioxidants. Here, we show for the first time that the selective induction of cell death by NADA in HSCs but not in hepatocytes implies a possible role for this novel endocannabinoid as an antifibrotic agent.
MATERIALS AND METHODS
HSC, Kupffer cell, liver sinusoidal endothelial cell, and hepatocyte isolation and culture. Primary HSCs were isolated by a two-step pronase-collagenase perfusion from the livers of male Sprague-Dawley rats (300 -450 g; n ϭ 20), from male Sprague-Dawley rats after 21 days of bile duct ligation (BDL) or sham operation (350 -400 g; n ϭ 3 each), or from C57BL/6J wild-type (25-30 g; n ϭ 32) or CB1 Ϫ/Ϫ CB2 Ϫ/Ϫ double knockout mice (25-30 g, pure C57BL/6J background; n ϭ 3) followed by Nycodenz (Axis-Shield, Oslo, Norway) two-layer discontinuous density gradient centrifugation as previously described (48, 50, 51) . The purity of HSC preparations was 94%, as assessed by autofluorescence at day 2 after isolation. HSCs were cultured on uncoated plastic tissue culture dishes as described previously. Rat and mouse HSCs were not passaged and were considered culture-activated between day 7 and 14 after isolation. Human primary culture activated HSCs were purchased from ScienCell Research Laboratories (Carlsbad, CA), cultured as previously described (51) and used between passages 1 to 5.
To isolate Kupffer cells from healthy C57BL/6J wild-type mouse livers (n ϭ 3), we performed collagenase-pronase perfusion followed by 15% Nycodenz gradient centrifugation and subsequent positive selection of F4/80-expressing cells by magnetic antibody cell sorting (Miltenyi Biotec, Bergisch Gladbach, Germany; Ref. 47) . Liver sinusoidal endothelial cells (LSECs) were isolated from healthy C57BL/6J wild-type mouse livers (n ϭ 3) after collagenase perfusion and 30% Nycodenz gradient centrifugation followed by magnetic antibody cell sorting using ␣CD146-beads (Miltenyi Biotec; Ref. 46) . Murine Kupffer cells and LSECs were not passaged and were cultured in DMEM containing 10% FBS.
Primary hepatocytes were isolated from male Sprague-Dawley rats (225-250 g; n ϭ 15) or from wild-type C57BL/6J mice (25-30 g, littermates; n ϭ 3) or FAAH Ϫ/Ϫ mice (25-30 g, pure C57BL/6J background; n ϭ 3) and cultured as described previously (50) . All animals received humane care, and all procedures were approved by the local committees for animal studies (Regierungspräsidium Karlsruhe and Cologne).
Experimental models of liver fibrosis. Liver fibrosis was induced in male C57BL/6J wild-type mice by intraperitoneal injections of CCl 4 (0.5 l/g body wt; 1:1 dilution with sterile mineral oil) twice a week for 4 wk (48). Control mice were treated with mineral oil alone (0.5 l/g body wt; 1:1 dilution with sterile PBS). For analysis of in vivo-activated primary HSCs, we applied a model of cholestatic liver fibrosis (3). Briefly, BDL or sham operation was performed in male Sprague-Dawley rats (n ϭ 3 each; 350 -400 g). After midline laparotomy, the common bile duct was ligated with 4 -0 silk two times and transected between the two ligations. The sham operation was performed likewise, with the exception of ligating and transecting the bile duct.
Isolation of dorsal root ganglia. As a positive control for THexpressing tissue, we used dorsal root ganglia (9) . C57BL/6J wildtype mice (25-30 g ) were killed by cervical dislocation. The spines of three mice were dissected and placed in a sterile culture dish. After the spine was opened, the dorsal root ganglia were dissected under a binocular microscope. The ganglia were carefully stripped of connective tissue with fine forceps and processed further mRNA isolation as described below.
TH immunohistochemistry. Human liver specimens were obtained according to the guidelines of the University of Bonn Ethics Committee from patients who had given their written informed consent. A paraffin-embedded liver biopsy specimen with normal liver histology or liver fibrosis due chronic hepatitis C virus infection (Desmet stage F1) was examined (n ϭ 4 each). Moreover, normal livers of vehicletreated or fibrotic livers of CCl 4-treated mice for 4 wk were examined (n ϭ 4). Immunohistochemistry using the TH antibody (Cayman Chemical, Ann Arbor, MI) in 1:200 dilution was performed on 4-m-thick paraffin-embedded sections by use of the peroxidaseconjugated avidin-biotin method following standard procedures (55) .
Measurement of endocannabinoid tissue levels. The levels of NADA were measured in rat striatum (n ϭ 4), liver tissue from CCl4-treated mice for 21 days or controls (n ϭ 8 each), liver tissue from male Sprague-Dawley rats 21 days after BDL or sham operation (n ϭ 8 each), as well as in liver tissue from the above described human liver samples (normal or fibrotic livers, F1; n ϭ 4 each) by liquid chromatography/mass spectrometry. The measurement was performed as previously described (22) with a minor modification: to monitor NADA and the deuterated internal standard two additional precursor-to-product ion transitions were added to the mass spectrometry method, i.e., m/z 440.3 ¡ 137.0 for NADA and m/z 448.3 ¡ 137.0 for NADA-d8. The levels of AEA were determined as previously described (48) in rat striatum (n ϭ 4) and in normal or fibrotic rat livers 21 days after BDL or sham operation (n ϭ 8 each).
Treatment of cells and detection of cell death. Cells were serum starved with DMEM containing 0.5% FCS for 12 h and treated either with NADA, AEA, or vehicle (ethanol; 0.1% final concentration), arachidonic acid, dopamine (all from Sigma-Aldrich, Deisenhofen, Germany), or actinomycin D (Sigma-Aldrich) plus murine TNF-␣ (R&D Systems, Minneapolis, MN). Where indicated, cells were pretreated with the pan-caspase inhibitor Val-Ala-Asp-fluoromethylketone (Z-VAD-FMK; R&D Systems); JNK inhibitor SP600125, FAAH inhibitor URB597, or CB1 antagonist AM251 (all Cayman Chemical, Ann Arbor, MI); CB2 antagonist SR144528 (Sanofi-Aventis, Montpellier, France); catechol-O-methyl-transferase (COMT) inhibitor OR-486 or receptor-interacting protein 1 (RIP1) inhibitor necrostatin-1 (both Tocris Bioscience, Bristol, UK); or TRPV1 antagonist capsazepine, TRPV1 agonist capsaicin, membrane cholesterol depletor methyl-␤-cyclodextrin, the antioxidants cell-permeable glutathione ethyl ester or Trolox, or the ␥-glutamyl cysteine synthase inhibitor DL-buthionine-(S,R)-sulfoximine (BSO; all Sigma-Aldrich). Cell death in HSCs and hepatocytes was measured by LDH release into the culture medium according to the manufacturer's instructions (Roche Diagnostics, Mannheim, Germany) and by propidium iodide (PI; Sigma-Aldrich) fluorescence. Apoptosis and necrosis were visualized by fluorescent microscopy of PI and annexin V staining (Roche) according to the manufacturer's instructions.
Detection of ROS. Serum-starved HSCs (2 ϫ 10 4 cells/well) plated in 24-well plates were loaded with the redox-sensitive dye 5-(and-6)-chloromethyl-2=,7=-dichlorodihydrofluorescein diacetate (Molecular Probes-Invitrogen, Darmstadt, Germany) for 30 min at 37°C, washed, and stimulated with NADA or AEA. ROS formation was measured for the indicated time in a multiwell fluorescence plate reader (Fluostar Optima; BMG, Offenburg, Germany) using excitation and emission filters of 485 and 535 nm, respectively (48, 50, 51) .
Western blot analysis. Electrophoresis of protein extracts and subsequent blotting were performed as described previously (48, 50, 51) . Blots were incubated with anti-TH, anti-FAAH (both Cayman Chemical); anti-caspase-3, anti-poly-(ADP-ribose) polymerase (anti-PARP), anti-phospho-ERK1/2, anti-AKT, anti-phospho-AKT (Thr308), antiphospho-NF-B p65 (Ser536), anti-phospho-JNK, or anti-RIP (all Cell Signaling Technologies, Beverly, MA, USA); or anti-COMT antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) at a dilution of 1:1,000 or with anti-␣-smooth muscle actin (␣-SMA; Sigma) at a dilution of 1:2,000 overnight at 4°C. After incubation with secondary horseradish-peroxidase conjugated antibody (Santa Cruz Biotechnology), the bands were visualized by the enhanced chemiluminescence light method (Amersham Biosciences) and exposed to X-omat film (Eastman Kodak, New Haven, CT) or a chemiluminescence imager (Image Station 2000R; Eastman Kodak). Blots were reprobed with anti-␤-actin mouse antibody (MP Biomedicals, Santa Ana, CA) as an internal control. Where indicated, the intensities of the detected bands were evaluated densitometrically using ImageJ (NIH, Bethesda, MD).
Quantitative RT-PCR analysis. RNA was extracted by the TRIzol method (Invitrogen, Darmstadt, Germany). After DNAse treatment, RNA was reverse transcribed into complementary DNA using random hexamer primers as described previously (50) and subsequently analyzed with the gene expression assay for TH (Applied Biosystems, Darmstadt, Germany; assay no. Mm00447557_m1). The PCR reaction was performed with a universal PCR master mix (Applied Biosystems) through the amplification of 10 ng of complementary DNA for 40 cycles (95°C for 15 s and 60°C for 1 min) on an ABI-Prism 7900HT sequence detection system. Each sample was measured in duplicate, and quantification was performed by comparing the threshold cycle (C t) values of each sample to a standard curve. Gene expression was normalized to 18S and is expressed as fold induction compared with hepatocytes or whole liver, respectively.
Wound healing assay. HSCs were cultured to confluence (Ͼ90%) in sixwell plates. After starvation with DMEM containing 0.5% FCS for 12 h, a 2-mm-wide linear wound in the cell monolayer was created using a pipette tip (4) . Cells were treated once daily with sublethal concentrations of NADA or vehicle only. Cells migrating into the wound were detected using a phase-contrast microscope at days 0, 4, and 6. Adenoviral infection. Construction of adenoviruses expressing fatty acid amid hydrolase (AdFAAH) or a green fluorescent protein-expressing control virus (AdGFP) have been previously described (50) . Rat HSCs were infected with AdFAAH or AdGFP at a multiplicity of infection of 50, achieving transduction rates of Ն90%. Cells underwent treatment with either NADA or AEA 24 h after initial infection.
Measurement of adenosine triphosphate levels. Human HSCs (4 ϫ 10 4 cells/well) were exposed to 25 and 100 M NADA for 30 min or TNF-␣/actinomycin D for 8 h. Cells were still alive and attached to the plate. Cellular ATP levels were quantified using a luciferin-and luciferase-based assay. Cells were rinsed with PBS and lysed with ATP-releasing buffer containing 100 mM potassium phosphate buffer at pH 7.8, 2 mM EDTA, 1 mM dithiothreitol, and 1% Triton X-100. ATP concentrations in lysates were quantified using an ATP determination kit (Invitrogen) according to the manufacturer's instructions and normalized to protein content.
Statistical analysis. All data represent the mean of three independent experiments Ϯ SE, if not otherwise stated. For the determination of statistical significance, unpaired Student's t-tests were performed using SigmaStat (SPSS, Chicago, IL). P values of Ͻ0.05 were considered to be statistically significant.
RESULTS
Mainly sympathetic neurons in the liver express the ratelimiting NADA-synthesizing enzyme TH. We found that TH as the rate-limiting NADA-producing enzyme was expressed in healthy liver as well as in injured and fibrotic liver of wild-type mice that have been treated with intraperitoneal injections of CCl 4 for 4 wk (Fig. 1A) . Interestingly, hepatocytes, but not activated HSCs, highly expressed TH (Fig. 1B) . In a quantitative RT-PCR analysis, hepatocytes expressed significantly higher mRNA levels of TH than the nonparenchymal cell populations HSCs, Kupffer cells, or LSECs (Fig. 1C) . However, TH mRNA levels of normal liver were ϳ1,800 times lower compared with dorsal root ganglion tissue that contains sympathetic neurons (9; Fig. 1D ). Accordingly, immunohistochemistry revealed sympathetic neurons in portal tracts as the main TH-expressing cell population in normal and fibrotic mouse or human liver (Fig. 1E) . Thus predominantly sympathetic neurons in the liver hold the enzymatic machinery to produce NADA in normal and fibrotic livers. After identification of the potential NADA-synthesizing liver cell population, we further sought to evaluate the liver tissue levels of the endocannabinoids NADA and AEA. Since NADA has previously been discovered and detected in rat striatum (8, 24) , we used this tissue to establish the method to measure NADA as well as AEA in normal and fibrotic liver tissue from mouse, rat, or humans. We found an approximate tissue level of NADA in rat striatum (n ϭ 4) of 1.0 nM and AEA of 30.1 nM (Fig. 1F , left). As previously described, NADA proved to be a very volatile molecule in peripheral tissues, including human plasma (1, 53). Thus we were not able to measure NADA levels in the livers of neither species. However, AEA was detectable in normal rat liver (n ϭ 8) at a level of 1.0 nM. In fibrotic livers (21 days after BDL), AEA was significantly upregulated to 2.9 nM, indicating the activation of the endocannabinoid system during liver injury and fibrogenesis (Fig.  1F, right) .
NADA efficiently mediates cell death in activated rat, mouse, and human HSCs. After addition to the culture media, NADA rapidly and dose dependently induced cell death in rat HSCs ( Fig. 2A) . After 2 h of NADA treatment, 23, 34, 55, and 69% of rat HSCs underwent cell death at concentrations of 10, 25, 50, and 100 M, respectively. Cell death was induced significantly after 4 h at NADA concentrations starting at 10 M. Cell death reached plateau levels after 4 h at NADA concentrations of 50 M and higher achieving a maximum of 86%. Concentrations Ͻ5 M did not induce significant death in HSCs during exposure time of up to 24 h. Similar results were obtained in primary mouse HSCs (Fig. 2B ) as well as in primary human HSCs (Fig. 2C ), which were even more susceptible towards NADA-induced cell death. Since especially NADA appeared to have a very short half life, we tested whether NADA was also able to induce cell death in activated HSCs after a very short time of exposure. Indeed, after an exposure time of 30 s, NADA led to similar induction of cell death than after an exposure time of 2 h (Fig. 2D) .
NADA effectively induces cell death in in vivo-activated HSCs. Since in vivo-activation of HSCs is considered to be the gold standard for the study of HSC biology (14) and to exclude the possibility that culture activation of HSCs artificially modulated their sensitivity to NADA-induced death, we performed BDL in rats for in vivo activation of HSCs. Twenty-one days after BDL, livers showed an increased expression of ␣-SMA (Fig. 2E , left) as a sign of increased activation of HSCs, compared with livers of sham-operated rats. HSCs isolated from fibrotic livers of BDL-treated rats showed an activated phenotype (Fig. 2E , middle) and considerably higher expression of ␣-SMA (Fig. 2E , right) in contrast to HSCs isolated from sham-operated rat livers. In vivo-activated HSCs were treated with NADA 24 h after isolation and were extremely sensitive to NADA-mediated cell death: HSCs already started to undergo cell death at concentrations Ͻ5 M 2 h after treatment (Fig. 2F ) and were efficiently killed after 4 h even at low concentrations of NADA (almost 60% cell death at 10 M).
NADA induces necrosis, but not apoptosis, in activated HSCs. To determine whether cell death induced by NADA was apoptotic or necrotic, we treated rat HSCs with either NADA, AEA, or actinomycin D and TNF-␣. Similar to AEA and in contrast to the apoptotic control actinomycin D/TNF-␣, NADAtreated HSCs displayed no annexin V staining but showed strong nuclear PI staining. Therefore, NADA-induced death appears to be necrotic (Fig. 3A) . HSCs treated with NADA showed cleavage of caspase 3 as displayed by Western blot in Fig. 3B . However, caspase inhibition with the pan-caspase inhibitor Z-VAD-FMK did not inhibit NADA-induced cell death in HSCs in contrast to TNF-␣/actinomycin D, indicating a caspase-independent form of cell death (Fig. 3C) . Moreover, NADA failed to induce PARP cleavage in HSCs as another hallmark of apoptotic cell death (data not shown), indicating that NADA-mediated cell death was indeed necrotic. To further examine, whether NADA-induced cell death involved features of programmed necrosis/necroptosis (56), we analyzed the expression of RIP1. RIP1 is essentially required for initiation of programmed necrosis and appeared to be slightly upregulated 60 min after NADA treatment (Fig. 3D, left) . However, treatment with the RIP1-inhibitor necrostatin-1 did not inhibit NADA-induced cell death (Fig. 3D, right) . Therefore, NADA did not induce necroptosis. Furthermore, NADAtreatment led to early depletion of ATP in contrast to the proapoptotic treatment with actinomycin D/TNF-␣, underlining the plain necrotic nature of NADA-caused cell death in HSCs (Fig. 3E) .
We further sought to analyze the signaling pathways involved in NADA-induced cell death and whether signaling pathways promoting stellate cell survival were possibly inhibited by NADA. Since we and others (32, 51) previously showed that AEA treatment in HSCs led to an activation of the JNK pathway, which may contribute to cell death, we performed Western blotting for phospho-JNK. NADA as well as PDGF-BB as positive control led to JNK phosphorylation ( 3F, left). However, pharmacological JNK inhibition through the small molecule inhibitor SP600125 did not reduce NADAmediated cell death (Fig. 3F, right) . Thus we could rule out a causative role of the JNK pathway in NADA-induced HSC death. Interestingly, NADA activated the AKT pathway, which is known to promote HSC survival (41) , in a similar way as PDGF-BB (Fig. 3G) . However, the apparent activation of this survival pathway was not sufficient to inhibit NADA-induced cell death. Moreover, activation of the NF-B pathway has also been linked to HSC survival (41) . We (51) have previously shown, that the endocannabinoid AEA was an inhibitor of TNF-␣-induced NF-B activation. NADA alone did not induce phosphorylation of the NF-B subunit p65 (data not shown).
To check for inhibition of NF-B by NADA, we pretreated HSCs with NADA before TNF-␣ exposure. In contrast to AEA (51), NADA did not inhibit NF-B p65 phosphorylation by TNF-␣ (Fig. 3) . Conversely, NF-B activation by TNF-␣ administration before NADA treatment did not inhibit NADAinduced cell death (data not shown). Thus the NF-B pathway was neither involved in NADA-induced cell death nor in survival signaling.
Sublethal doses of NADA reduce activation, proliferation, and migration in HSCs. Since we found that AEA was able to inhibit HSC proliferation in activated primary HSCs in sublethal doses (51), we tested the effects of NADA (1 M) on proliferation and migration of fully activated primary rat HSCs in a wound healing assay. Cells treated with vehicle only were able to proliferate and migrate into the wound to nearly close it after 6 days. NADA treatment, however, almost completely inhibited HSC proliferation and migration (Fig. 4A) . To elucidate the mechanism behind the inhibition of HSC proliferation and migration, we examined the effect of NADA on proproliferative signaling. Incubation of HSCs with 10% FBS in the culture media led to marked ERK1/2 phosphorylation, which could be inhibited by exposure of the cells to NADA (0.1 M; Fig. 4B ). We further sought to investigate whether exposure to sublethal concentrations of NADA prevented activation of primary HSCs. Interestingly, we were able to detect significantly lower expression of ␣-SMA as a marker of HSC activation after daily treatment of freshly isolated primary mouse HSCs with NADA (1 M) in a time course of 7 days (Fig. 4C, top and bottom) . At a dose of 0.1 M daily, this effect was still detectable, yet not statistically significant (Fig. 4C, top  and bottom) . NADA-induced death in HSCs occurs independently of the cannabinoid receptors CB1, CB2, or TRPV1. NADA was shown to be a full agonist at CB1 receptors and TRPV1 receptors and to a lesser extent at CB2 receptors (6, 24). Since we have (51) previously shown that these receptors are expressed in HSCs, we investigated whether HSC death is mediated by these receptors in response to NADA using both pharmacologic and genetic approaches. NADA-induced cell death was neither blocked by AM251, a specific antagonist of CB1, nor by SR144528 (SR2), a specific antagonist of CB2, nor by capsazepine, a specific antagonist of TRPV1 (Fig. 5A) , indicating that NADA induces cell death independently of these receptors. None of the inhibitors alone did induce cell death in HSCs (Fig. 5A) . We further confirmed these findings in HSCs isolated from CB1/CB2 Ϫ/Ϫ double knockout mice compared with HSCs from wild-type mice (Fig. 5B) . Since several previous studies (13, 45) have shown that NADA induced cell death in certain cell types via TRPV1 activation, we checked whether the specific TRPV1 agonist capsaicin induced cell death in primary activated mouse HSCs. In contrast to NADA, capsaicin did not induce cell death in doses up to 100 M in HSCs (Fig. 5C ). This underlines the clear independence of NADA-mediated cell death from TRPV1 signaling.
NADA-induced cell death does not depend on membrane cholesterol. Various studies in several different cell types have shown that AEA induces cell death independently of CB1, CB2, or TRPV1 through interaction with membrane cholesterol, possibly via cholesterol-rich lipid rafts (15, 16) . Accordingly, membrane cholesterol depletion by methyl-␤-cyclodextrin preincubation completely inhibited necrosis induced by 25 M AEA but not by 25 M NADA (Fig. 5D ), indicating that NADA does not require interaction with membrane cholesterol for cellular uptake and subsequent induction of cell death in HSCs.
NADA-induced necrosis depends on intracellular ROS formation. NADA caused a marked and rapid increase in ROS formation (Fig. 6A ) that occurred predominantly cytoplasmatically as well as intranuclearly (Fig. 6B ). ROS generation induced by NADA was dose dependent, and the extent was similar to that of AEA at same concentrations (Fig. 6A) . Pretreatment with the antioxidants glutathione ethyl ester or Trolox significantly reduced NADA-mediated cell death (Fig.  6 , C and D; P Ͻ 0.001 vs. NADA alone), indicating that ROS substantially contribute to NADA-induced cell death. To provide further evidence for ROS as a key mediator of cytotoxic NADA signaling, we tested the effects of GSH depletion on NADA-induced cell death in HSCs. We found a significant, nearly 50% increase in cell death after 2 h of NADA treatment (10 M) in HSCs that had been depleted of GSH by pretreatment with the ␥-glutamyl cysteine synthase inhibitor BSO ( Fig. 6E ; P Ͻ 0.05 vs. NADA alone), supporting our hypothesis that ROS mediate cytotoxic NADA signals.
NADA does not induce cell death in primary hepatocytes. To underline the antifibrotic potential of NADA by effective induction of cell death in HSCs and to exclude possible adverse effects of NADA on parenchymal cells of the liver, we exposed primary rat hepatocytes to increasing concentrations of NADA for up to 24 h. In contrast to HSCs, primary rat hepatocytes were resistant against cell death up to 100 M NADA for 24 h (Fig. 7A) . We obtained similar results with primary mouse hepatocytes (data not shown). Thus the exorbitant differences in cell death susceptibility of HSCs and hepatocytes imply that NADA selectively induces cell death in the main fibrogenic cells of the liver but not in hepatocytes.
FAAH determines resistance to NADA-mediated death in hepatocytes. Next, we examined the mechanisms behind this discrepancy of cell death susceptibility towards NADA of HSCs and hepatocytes. First we checked whether primary mouse HSCs or hepatocytes express COMT, which has previ- ously been described as a NADA-degrading enzyme (24) . Neither HSCs nor hepatocytes showed a detectable expression of COMT (Fig. 7B) . Conversely, primary mouse hepatocytes expressed large amounts of FAAH in contrast to HSCs (Fig.  7C) , which has been also attributed to NADA degradation (24) . When we applied NADA to hepatocytes that had been pretreated with the selective COMT inhibitor OR-486, we were not able to detect a significant induction of cell death (Fig. 7D) . Thus we could rule out any contribution of this NADA degradation enzyme to the different susceptibility toward NADAinduced cell death in HSCs and hepatocytes. To investigate whether the differential expression of FAAH may contribute to the resistance of hepatocytes to NADA-induced cell death, we blocked FAAH activity by preincubation with URB597, a highly selective FAAH inhibitor (Fig. 7E) . Interestingly, URB597 increased NADA-induced cell death in hepatocytes up to 43% at a concentration of 25 M. Incubation with URB597 alone did not induce any cell death (data not shown). This significant contribution of FAAH to the remarkable resistance of hepatocytes against NADA-induced cell death could be confirmed in FAAH Ϫ/Ϫ hepatocytes. Hepatocytes lacking FAAH were highly susceptible towards NADA with 28, 46, and 61% of dead cells after 10, 25, and 50 M NADA, respectively (Fig. 7F) . To further investigate the role of FAAH, rat HSCs were infected with an adenovirus expressing rat FAAH, which allowed us to overexpress this enzyme in HSCs. Infection resulted in a strong expression of FAAH (Fig. 8A) . AdFAAH treatment of HSCs decreased NADA-induced cell death (25 M) from 55 to 23%, similarly to AEA-induced cell death (Fig. 7C) . In contrast, HSCs infected with the control virus expressing only GFP showed no difference in NADA-induced cell death (Fig. 8, B and C) . To exclude that NADA-induced cell death in primary HSCs was mediated by the putative metabolites of NADA, dopamine or arachidonic acid, and to finally prove that FAAH-mediated degradation of NADA into these metabolites terminates NADA toxicity, we incubated primary mouse HSCs with 25 M of each substance for 4 h (Fig. 8D) . In contrast to NADA, neither arachidonic acid nor dopamine induced significant cell death. To further rule out that the induction of cell death in HSCs by NADA was an unspecific effect simply due to its nature as a reactive lipid mediator, we compared the substance to its precursor/metabolite arachidonic acid and to prostaglandin D 2 (PGD 2 ), another alternative lipid molecule that is involved in a COX-2-dependent endocannabinoid metabolism pathway (29) . Interestingly, even in high concentrations up to 100 M, neither arachidonic acid nor PGD 2 induced cell death in HSCs in contrast to NADA (Fig. 8E) .
GSH levels also render hepatocytes resistant towards NADA-mediated death. Due to the fact that ROS formation is crucial for the cytotoxic effect of NADA in HSCs, we determined whether antioxidants are an additional mechanism for the resistance to NADA-induced cell death in hepatocytes. Previously, we (51) already showed that hepatocytes express GSH levels that are 10-fold higher than in HSCs. Accordingly, pretreatment with BSO rendered hepatocytes sensitive to NADA-induced cell death, leading to 28% cell death after treatment with 25 M NADA for 24 h (Fig. 7E) . When hepatocytes were pretreated with a combination of BSO and URB597, NADA induced Ͼ50% cell death at a concentration of 50 M (Fig. 7E) , and the threshold for NADA-induced cell death was lowered to 1 M (data not shown). Thus FAAH and GSH are main determinants of NADA-induced cell death in the liver.
DISCUSSION
The capability to induce cell death in many different cell types has made endocannabinoids appealing targets for cancer, inflammatory, or degenerative diseases (16, 33) . Knowledge about the mechanisms that determine the susceptibility of primary cells toward the different types of endocannabinoids may be helpful for therapeutic exploitation of the endocannabinoid system.
Recently, it has been demonstrated that the endocannabinoid system is involved in the regulation of fibrogenesis in the liver. CB2 Ϫ/Ϫ mice showed increased fibrogenesis in response to CCl 4 injection, whereas CB1 Ϫ/Ϫ mice had decreased hepatic fibrogenesis (26, 52) . However, the mechanisms by which endocannabinoids regulate liver injury and fibrogenesis are not well characterized and require further investigation (49).
We have recently described that the endocannabinoids AEA or 2-AG selectively induce cell death in primary HSCs, the main fibrogenic cell type of the liver, but do not induce death in primary hepatocytes (48, 51) . These actions occur independently of cannabinoid receptors but require membrane cholesterol. A selective induction of cell death in HSCs may contribute to the resolution of liver fibrosis, whereas hepatocyte cell death deteriorates liver function and promotes fibrogenesis (2) . These properties suggest that modulation of the endocannabinoid system may be useful for the treatment of hepatic injury and fibrosis. However, it is yet unclear which endocannabi- noids are responsible for the profibrotic signaling action of CB1 (52) or the antifibrotic effects of CB2 stimulation (26) . In a recent study, Caraceni et al. (10) found a relevant increase in serum levels of the novel endocannabinoids oleyl ethanolamine and palmitoyl ethanolamine of human patients with liver cirrhosis, but the functional role of these endocannabinoids on cellular basis was not analyzed.
Here we demonstrate that the novel endocannabinoid NADA dose dependently induces death in activated primary HSCs, but not in hepatocytes, through an ROS-dependent mechanism independently from the cannabinoid receptors CB1 or CB2 or the vanilloid receptor TRPV1. Similar to HSC death induced by AEA, NADA rapidly and effectively caused necrotic cell death in HSCs starting at low micromolar concentrations. NADA-induced cell death appeared to be caspase 3-independent necrosis, since pan-caspase inhibition with Z-VAD-FMK only inhibited TNF-␣-induced HSC apoptosis but not NADAinduced death.
Since endocannabinoids exhibit a volatile nature with short half-life due to their production on demand without storage capability and fast degradation (16) , the rapid induction of cell death in primary HSCs by NADA shown in vitro implies a putative effective induction of death in vivo. NADA tissue levels in vivo were determined to be in comparable ranges as AEA in the rat striatum (24) . Hepatic tissue levels of AEA as well as 2-AG have been shown to be significantly upregulated in the injured liver (25, 39, 48) . AEA was determined to rise up to 2.0 nM (25) , and 2-AG was even measured to be elevated up to 2.2 M (25, 48). We were able to detect NADA as well as AEA levels in the rat striatum also in the nanomolar range, which is consistent with previous reports (8, 23, 24) . However, several groups were not able to detect NADA neither in the central nervous system (11, 30) nor in peripheral tissues or plasma (1, 53) , indicating an extremely volatile and short-lived nature of this novel endocannabinoid. Accordingly, we were unable to measure NADA levels in livers from mice, rats, or humans. It might be possible that NADA is not produced in the liver under our conditions. Yet, we detected AEA levels in low nanomolar ranges in normal liver, and we found a significant, threefold increase in fibrotic liver, indicating the activation of the endocannabinoid system during liver injury and fibrogenesis. For interpretation of endocannabinoid levels in vivo, one has to keep in mind that endocannabinoids are produced instantly on demand and are rapidly degraded. Therefore, the detected endocannabinoid tissue concentrations might be significantly lower than the actual concentrations on the cellular level. At sites of proinflammatory cell activation, AEA levels could reach up to 50 M intracellularly (7) . Thus it might be conceivable that concentrations of NADA may also quickly reach micromolar ranges on the cellular level that could exert antiproliferative or antifibrogenic actions or even rapidly induce cell death in vivo, since we were able to show that in vivo-activated HSCs were highly susceptible toward NADA and a very short exposure time was sufficient to effectively induce cell death in HSCs. However, further studies with exogenously applied NADA in models of murine liver fibrosis could corroborate the potential of NADA as an antifibrogenic tool.
When we tested the effects of sublethal concentrations of NADA on activated primary HSCs, we found a notable inhibitory effect on proliferation and migration, as shown in the wound healing assay. To our knowledge, this is the first report on putative antiproliferative properties of NADA. This finding exceeds the antiproliferative properties of AEA, where we at least found an inhibition of DNA synthesis at concentrations between 1 and 10 M but not at nanomolar concentrations (51) . When we examined the molecular mechanisms of the antiproliferative effect of NADA, we found an inhibition of ERK1/2 phosphorylation by NADA after addition of proproliferative FBS to serum-starved HSCs. ERK has been shown to be a kinase that mediates proproliferative and antiapoptotic effects in myofibroblasts and HSCs (52) . Moreover, NADA in sublethal concentrations was also able to slow down activation of freshly isolated primary mouse HSCs, which in contrast could not be achieved by comparable concentrations of AEA (51) . This finding represents another aspect of the antifibrotic properties of NADA in the liver.
Concerning the pathways of NADA-induced cell death, previous studies reported NADA-mediated cell death through engagement of TRPV1 or CB2 receptors. One study (45) found NADA-induced death in human peripheral blood mononuclear cells that could be inhibited by pharmacological blockade of either TRPV1 or CB2 receptors. Whether NADA induced apoptotic or necrotic cell death was not analyzed. Another study (13) described a delayed form of cell death with apoptotic features in a neuronal cell line stably expressing recombinant human TRPV1. Untransfected cells of the same cell type were resistant against NADA. Although HSCs express all three putative cannabinoid or vanilloid receptors CB1, CB2, and TRPV1 (26, 51), we found a receptor-independent form of NADA-mediated necrotic cell death in HSCs, shown by pharmacologic and genetic approaches of receptor antagonism. We further tested, whether TRPV1 activation could generally induce HSC cell death. When we exposed HSCs to the specific TRPV1 agonist capsaicin, we did not observe any cell death even at concentrations up to 100 M. The differences of NADA-mediated type of cell death or dependence on CB2 or TRPV1 receptors might be due to different cell types, since we and others (26, 50, 51) have demonstrated earlier that endocannabinoids, i.e., AEA or 2-AG, induce cell death in HSCs independently from CB1, CB2, or TRPV1. However, we also previously showed that AEA-mediated death occurred through interaction of AEA with membrane cholesterol. In contrast to AEA, NADA-induced HSC death could not be inhibited by membrane cholesterol depletion, indicating common downstream death signaling pathways of NADA and AEA but different upstream mechanisms. Cholesterol was shown to stimulate the insertion of AEA into, and its transport across lipid bilayer membranes, because AEA could adopt a shape that was remarkably complementary to cholesterol (18) . This might not be the case for NADA. Recent studies (54) have suggested that endocannabinoids reach their site of action in cells through fast lateral diffusion across cell membrane bilayers. To do so, endocannabinoids such as AEA and 2-AG seem to require cholesterol, but NADA apparently does not.
Downstream mechanisms of NADA-induced death in HSCs comprise the rapid and substantial induction of ROS in similar ranges as AEA. ROS have previously been proposed as mediators of HSC activation and proliferation (4, 19) . However, the proproliferative and activating effects of ROS in HSCs are mediated by low-level generation by membrane-bound NADPH oxidase. In contrast, our study detects high levels of rapid ROS production after NADA treatment predominantly generated in the cytoplasm. High amounts of rapidly generated ROS are known to decrease cellular oxidative defense mechanisms, causing lipid peroxidation and leading to rapid damage of vitally important intracellular macromolecules, thus initiating necrosis (43) . The fact that treatment of HSCs with antioxidants (GSH, Trolox) blocked and GSH depletion aggravated NADA-induced cell death underlines the pivotal role of ROS generation for HSC death induction. Moreover, ROS trigger the loss of cellular ATP by directly damaging mitochondrial DNA, enzymes such as ATP synthase, and cell organelle membranes (21, 43) . We detected an early depletion of ATP in NADA-treated HSCs, one of the key characteristics of necrotic cell death (31, 34) . ATP depletion causes inactivation of Na ϩ -K ϩ -ATPase entailing accumulation of intracellular Na ϩ and loss of K ϩ , accompanied by Cl Ϫ increase and water influx with subsequent cell swelling and membrane blebbing (43) , features that occur in HSCs after NADA treatment. To further analyze the signaling pathways leading to necrotic cell death by NADA in HSCs, we checked for the involvement of RIP1 as a key component of programmed necrosis/necroptosis. Programmed necrosis has been identified as a regulated mechanism of cell death when apoptosis is blocked and has been linked to ROS induction (56) . However, inhibition of RIP1 did not inhibit NADA-mediated death, indicating that NADA does not induce necroptosis but pure necrosis. Other signaling pathways that are known to be affected by endocannabinoids and have concomitantly been related to cell death or survival of HSCs involving ROS are the JNK, NF-B (51), and AKT (40) pathways. NADA led to JNK activation, which, however, did not causatively contribute to NADA-induced cell death. In contrast to AEA, NADA neither activated nor inhibited NF-B activation. Finally, NADA phosphorylated AKT, but this protective pathway could not inhibit NADA-induced cell death. Thus NADA cell death signaling in HSCs appears to depend on excessive ROS production with subsequent initiation of intracellular damage and ATP depletion without requirement of JNK activation, or inhibition of NF-B or AKT, respectively.
The induction of cell death in HSCs by NADA was highly effective compared with other lipid mediators. We compared NADA to its precursor/metabolite arachidonic acid (23) and the arachidonic acid derivative PGD 2 , which plays an important role in COX-2-mediated degradation of endocannabinoids (29) . All substances feature polyunsaturated acyl chains that might induce cell death because of detergent-like perturbation of the cell membrane and increased ROS formation followed by lipid peroxidation (42) . The significantly higher rate of cell death by NADA even when we applied excessive concentrations of the control substances up to 100 M might be due to structural differences between these substances leading to lower binding of arachidonic acid or PGD 2 to HSCs with subsequently lower toxicity.
In our initial analysis of expression of the rate-limiting NADA-generating enzyme TH (24), we found a stable expression pattern in normal as well as in fibrotic liver. Strikingly, TH was mainly expressed in sympathetic neurons that run along the portal tracts, suggesting that this nerval tissue might be the putative main source of NADA in the liver. Hepatocytes express TH on mRNA and protein levels but to a significantly lower level than sympathetic nerval tissue. Nonparenchymal cells such as HSCs, Kupffer cells or LSECs only express scarce traces of the enzyme. Therefore, in contrast to NADA degradation, neither hepatocytes nor nonparenchymal cell populations seem to be critically involved in the generation of NADA in the liver.
Interestingly, hepatocytes were largely resistant against cell death induced by NADA in contrast to HSCs. This remarkable resistance of hepatocytes against NADA death was due to the effective antioxidant defense mechanism of high GSH expression. However, in pathological conditions such as advanced liver cirrhosis or alcoholic liver disease, hepatic antioxidant defense mechanisms, e.g., GSH levels, are severely diminished (2) . The reduction of antioxidants could render hepatocytes highly susceptible toward the deleterious effects of oxidative lipid mediators such as polyunsaturated free fatty acids or endocannabinoids. Due to the fact that antioxidant levels confer only partial resistance against NADA in hepatocytes and could be significantly depleted in vivo, we analyzed additional factors that caused hepatocyte resistance against NADA-induced death. Methylation represents one mechanism for the partial inactivation of NADA (24) . NADA is converted by catechol-o-methyl-transferase (COMT) to its less potent 3-Omethyl derivative. However, COMT expression was neither significantly detectable in hepatocytes nor in HSCs. Consequently, this degradation pathway did not contribute to the NADA resistance of hepatocytes, since selective pharmacological inhibition of COMT did not render hepatocytes susceptible toward NADA death. Another more effective degradation pathway of NADA is its hydrolyzation by FAAH into arachidonic acid and dopamine (23, 24) . FAAH has initially been identified as the primary degradation enzyme for AEA (12) . FAAH is highly expressed in hepatocytes but not in HSCs and has been shown by our group to play a pivotal role in the resistance of hepatocytes against AEA-induced cell death (50). When we inhibited FAAH with the selective FAAH inhibitor URB597, we were able to make hepatocytes susceptible toward NADA and in addition, FAAH Ϫ/Ϫ hepatocytes displayed a high vulnerability for NADA. Thus like AEA, NADA does not induce cell death in hepatocytes unless they are severely depleted of GSH or FAAH has been inactivated. As a proof of principle, adenoviral overexpression of FAAH in HSCs conferred resistance against NADA, underlining the pivotal role of FAAH in the resistance of liver cell populations against NADA. These crucial protective properties of FAAH against endocannabinoids possibly apply also to pathological liver conditions that are accompanied by reduced antioxidant defense levels. Another evidence of the importance of FAAH in NADA resistance was the fact that the hydrolyzation products arachidonic acid and dopamine did not induce cell death in HSCs. However, it has been shown that AEA was a better substrate for FAAH than NADA (23, 24) , possibly explaining the slightly higher resistance of hepatocytes against AEA-than NADA-induced cell death. FAAH was also shown to be a putative synthesizing enzyme for NADA (23) , but since FAAH primarily conferred cellular resistance against NADAinduced cell death, we assume rather an essential role for FAAH in NADA degradation in these liver cell populations than in NADA synthesis.
In conclusion, the selective expression of effective defense systems (antioxidants and FAAH) in hepatocytes as well as the selective and efficient induction of cell death in HSCs and its inhibitory effects on HSC activation and proliferation propose NADA as a novel antifibrotic agent.
